Impact of Anti-Inflammatory Drugs on Pyogenic Vertebral Osteomyelitis: A Prospective Cohort Study

Abstract

Objective. Pyogenic vertebral osteomyelitis (PVO) are frequently misdiagnosed and patients often receive anti-inflammatory drugs for their back pain. We studied the impact of these medications. Methods. We performed a prospective study enrolling patients with PVO and categorized them depending on their drugs intake. Then, we compared diagnosis delay, clinical presentation at hospitalization, incidence of complications, and cure rate. Results. In total, 79 patients were included. Multivariate analysis found no correlation between anti-inflammatory drug intake and diagnosis delay, clinical presentation, complications, or outcome. Conclusion. Anti-inflammatory drugs intake does not affect diagnostic delay, severity at diagnosis, or complications of PVO.

Celecoxib for Management of Refractory Back Pain Secondary to Vertebral Osteomyelitis: A Case Report

“…A study by Reuben et al demonstrated no significant differences in the number of bone healing complications using celecoxib compared to those patients who did not receive NSAIDs [9]. A recent prospective cohort study confirmed these findings [15]. These conclusions suggest that celecoxib would not likely increase the risk of bone-related complications in VO managed either conservatively or operatively.…”

Ubiquitin-Specific Peptidase 8 Is Critical for the Onset of Infectious Osteomyelitis by Targeting RIPK2 Ubiquitination

“…The long-term inflammatory conditions further cause chronic osteomyelitis, where the increase of leucocytes and cytokines accompanied by fibrosis can be observed (11). Interestingly, the inhibition of inflammation is regarded as an effective strategy in osteomyelitis therapy, which is supported by numerous studies (12,13). For instance, nonsteroidal anti-inflammatory drugs (NSAIDs) and antibiotics are commonly recommended in osteomyelitis therapy in part by attenuating inflammation symptoms and suppressing inflammatory cytokines (12,14).…”